{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:49:00Z","timestamp":1790732940757,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T00:00:00Z","timestamp":1637798400000},"content-version":"vor","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Int AIDS Soc."],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Short\u2010course preventive therapy with 1\u2010month course of daily administration of isoniazid (300\u2010mg) plus rifapentine (600\u2010mg) (1HP) and 3\u2010month course of weekly administration of isoniazid (900\u2010mg) plus rifapentine (900\u2010mg) (3HP) has higher completion rates than 9\u2010month course of daily isoniazid (9H) for individuals with latent tuberculosis infection (LTBI). We aimed to evaluate the effect, safety and tolerability of 1HP in people living with HIV (PLWH) and LTBI who received coformulated bictegravir\/emtricitabine\/tenofovir alafenamide (BIC\/FTC\/TAF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PLWH testing positive by interferon\u2010gamma release assay and having received BIC\/FTC\/TAF for &gt;2 weeks with plasma HIV RNA load (PVL) &lt;200 copies\/ml were enrolled. BIC trough plasma concentrations and cytokine profiles were determined before the first dose (day 1\/baseline), 24 h after the 14th (day 15) and 28th (day 29) doses of 1HP. PVL were determined on days 15 and 29 of 1HP and every 3 months subsequently after discontinuation of 1HP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From November 2019 to December 2020, 48 PLWH with LTBI were enrolled. One participant (2.1%) discontinued 1HP on day 15 due to fever and generalized rashes with PVL of 72 copies\/ml, which was &lt;50 copies\/ml in three subsequent determinations while on BIC\/FTC\/TAF over the 12 months of follow\u2010up. The percentages of BIC trough plasma concentrations above the protein\u2010adjusted 95% effective concentration (paEC<jats:sub>95<\/jats:sub> = 162 ng\/ml) were 56.3% and 37.0% on days 15 and 29, respectively. The percentage of PVL &lt;200 copies\/ml was 91.7% on day 15, 97.8% on day 29 and 100% at both months 3 and 6. After a median observation of 52 weeks (interquartile range, 51\u201355), all participants continued BIC\/FTC\/TAF with a median PVL of 20 copies\/ml (range 20\u2013331). Except for the participant who discontinued 1HP because of allergic reactions, none of the participants had relevant symptoms or increases of the cytokine levels assessed between baseline and days 15 and 29 of 1HP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>BIC\/FTC\/TAF in combination with 1HP was well tolerated with a high completion rate. BIC trough plasma concentrations were significantly decreased with concurrent use of 1HP among PLWH with LTBI. While transient viral blips were observed during 1HP without causing subsequent treatment failure, such combination should be applied with caution.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jia2.25844","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T10:39:05Z","timestamp":1637923145000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Short\u2010course daily isoniazid and rifapentine for latent tuberculosis infection in people living with HIV who received coformulated bictegravir\/emtricitabine\/tenofovir alafenamide"],"prefix":"10.1002","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3241-5492","authenticated-orcid":false,"given":"Bo\u2010Huang","family":"Liou","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Hsinchu MacKay Memorial Hospital  Hsinchu City Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih\u2010Ning","family":"Cheng","sequence":"additional","affiliation":[{"name":"School of Pharmacy National Taiwan University  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya\u2010Ting","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Pharmacy National Taiwan University  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Jou","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy National Taiwan University Hospital and National Taiwan University College of Medicine  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu\u2010Chung","family":"Chuang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine National Taiwan University Hospital and National Taiwan University College of Medicine  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan\u2010Yin","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine National Taiwan University Hospital and National Taiwan University College of Medicine  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen\u2010Chun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine National Taiwan University Hospital and National Taiwan University College of Medicine  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu\u2010Wen","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Pharmacy National Taiwan University  Taipei Taiwan"},{"name":"Department of Pharmacy National Taiwan University Hospital and National Taiwan University College of Medicine  Taipei Taiwan"},{"name":"Graduate Institute of Clinical Pharmacy National Taiwan University College of Medicine  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching\u2010Hua","family":"Kuo","sequence":"additional","affiliation":[{"name":"School of Pharmacy National Taiwan University  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8145-1900","authenticated-orcid":false,"given":"Hsin\u2010Yun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine National Taiwan University Hospital and National Taiwan University College of Medicine  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7345-0836","authenticated-orcid":false,"given":"Chien\u2010Ching","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine National Taiwan University Hospital and National Taiwan University College of Medicine  Taipei Taiwan"},{"name":"Department of Tropical Medicine and Parasitology National Taiwan University College of Medicine  Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,11,25]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"World Health Organization. Global Tuberculosis Report 2020. Available at:https:\/\/www.who.int\/publications\/i\/item\/9789240013131. Accessed 1 February 2021."},{"key":"e_1_2_11_3_1","unstructured":"World Health Organization. Latent TB infection: updated and consolidated guidelines for programmatic management. Available at:https:\/\/www.who.int\/publications\u2010detail\u2010redirect\/9789241550239. Accessed 1 February 2021."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60162-8"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507198"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30372-8"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328216f441"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328327964f"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1806808"},{"key":"e_1_2_11_10_1","unstructured":"US Department of Health Human Service"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ464"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa470"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30032-1"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt483"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy082"},{"key":"e_1_2_11_16_1","unstructured":"US Department of Health Human Service"},{"key":"e_1_2_11_17_1","unstructured":"European AIDS Clinical Society.EACS guidelines version 10.1. Available at:https:\/\/www.eacsociety.org\/guidelines\/eacs\u2010guidelines\/eacs\u2010guidelines.html. Accessed 1 February 2021."},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00449-z"},{"key":"e_1_2_11_19_1","unstructured":"Gilead SciencesBiktarvy\u00ae (bictegravir emtricitabine and tenofovir alafenamide): US prescribing information. Available at:https:\/\/www.accessdata.fda.gov\/. Accessed 1 February 2021."},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-16"},{"key":"e_1_2_11_21_1","unstructured":"Taiwan AIDS Society. Guidelines for diagnosis and treatment of HIV\/AIDS 6th edition. 2020. Available athttp:\/\/www.aids\u2010care.org.tw\/journal\/treatment.aspAccessed 1 February 2021."},{"key":"e_1_2_11_22_1","unstructured":"CustodioJM WestSK CollinsS VuA XiaoD MartinH et\u00a0al.Pharmacokinetics of bictegravir administered twice daily in combination with rifampin.Abstract 34. Conference on Retroviruses and Opportunistic Infections.Boston MA 2018."},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e328312972e"},{"key":"e_1_2_11_24_1","unstructured":"AcostaRK AndreattaK D'AntoniML CollinsS MartinH WhiteKL.HIV viral blips in adults treated with InSTI\u2010based regimens throught 144 weeks. Abs. No. 540.Virtual Conference on Retroviruses and Opportunistic Infections.Boston MA 2020."},{"key":"e_1_2_11_25_1","unstructured":"AroraP CollinsSE MartinH ZhangX MakL LingJ et\u00a0al.Drug interactions with once\u2010daily B\/F\/TAF in combination with once\u2010weekly rifapentine.Abs. No. 369. Virtual Conference on Retroviruses and Opportunistic Infections.2021."},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz068"},{"key":"e_1_2_11_27_1","unstructured":"LutzJD ShaoY LingJ CustodioJM MartinH QuirkE et\u00a0al.Bictegravir\/emtricitabine\/tenofovir alafenamide phase 3 exposure\u2010response analysis of safety and efficacy in the treatment of HIV infection. The 19th International Workshop on Clinical Pharmacology of Antiviral Therapy.Baltimore MD 2018."},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201912-2489OC"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182965d45"}],"container-title":["Journal of the International AIDS Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.25844","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jia2.25844","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jia2.25844","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T09:05:47Z","timestamp":1693213547000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jia2.25844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/jia2.25844"],"URL":"https:\/\/doi.org\/10.1002\/jia2.25844","archive":["Portico"],"relation":{},"ISSN":["1758-2652","1758-2652"],"issn-type":[{"value":"1758-2652","type":"print"},{"value":"1758-2652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"2021-04-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-27","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e25844"}}